Cargando…
Verapamil potentiation of doxorubicin resistance development in B16 melanoma cells both in vitro and in vivo.
The effect of the combined administration of doxorubicin (DX) and verapamil (VRP) on the induction of DX resistance of B16 melanoma cells, was investigated both in vitro and in vivo. Cells grown in the presence of increasing concentrations of DX and of 1 microM VRP, tested at several passages, were...
Autores principales: | Formelli, F., Supino, R., Cleris, L., Mariani, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246578/ https://www.ncbi.nlm.nih.gov/pubmed/3390370 |
Ejemplares similares
-
In vivo characterization of a doxorubicin resistant B16 melanoma cell line.
por: Formelli, F., et al.
Publicado: (1986) -
Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention.
por: Supino, R., et al.
Publicado: (1986) -
Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line.
por: Supino, R., et al.
Publicado: (1988) -
CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma
por: Zhang, Tengyue, et al.
Publicado: (2017) -
Phase I and pharmacokinetic study of D-verapamil and doxorubicin.
por: Bissett, D., et al.
Publicado: (1991)